Comparative Pharmacology
Head-to-head clinical analysis: DORIDEN versus ETHCHLORVYNOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIDEN versus ETHCHLORVYNOL.
DORIDEN vs ETHCHLORVYNOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate-like sedative-hypnotic; acts on GABA-A receptors to enhance inhibitory neurotransmission, causing CNS depression.
Ethchlorvynol is a sedative-hypnotic with central nervous system depressant effects. Its exact mechanism is unknown, but it may potentiate GABA activity or depress neuronal excitability.
500 mg orally at bedtime, maximum 1 g per day; for sedation, 250 mg 3 times daily after meals.
500 mg to 1 g orally at bedtime as needed for insomnia.
None Documented
None Documented
Terminal elimination half-life is 4-10 hours in healthy adults; prolonged in elderly and patients with hepatic impairment, increasing to 12-20 hours.
Clinical Note
moderateEthchlorvynol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate."
Clinical Note
moderateEthchlorvynol + Clemastine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine."
Clinical Note
moderateEthchlorvynol + Venlafaxine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine."
Clinical Note
moderate10-25 minutes (initial rapid distribution phase); terminal elimination half-life approximately 4-6 hours in adults (prolonged in liver disease due to reduced clearance).
Renal (accounting for approximately 80% of elimination, primarily as glucuronide conjugates and unchanged drug); biliary/fecal (minor, about 10%).
Renal: <1% unchanged; Hepatic metabolism to inactive conjugates; Fecal: minimal. Approximately 90% of a dose is excreted in urine as glucuronide conjugates within 24 hours.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic
Ethchlorvynol + Nefazodone
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone."